Our research presented great predictive performance of PAPS in predicting the drug sensitivity to Axitinib in HCC; it suggested that the PI3K/AKT/mTOR pathway might be involved in the mechanism of Axitinib resistance in HCC, but the concrete mechanism should be further explored. Here, MTOR is linked to hepatocellular carcinoma.